Does your report show a rarer change? Each one is explained here in the same way: what it means, how common it is and which treatments are authorised in the EU.
4 min read
Updated 17 November 2026
Most important in brief
Each rare change affects 1 to 3 in 100 people with NSCLC, but together they affect many.
For BRAF V600E or RET, tablets are available as the first treatment.
For MET exon 14, HER2 or NTRK, targeted medicines in the EU usually come after a first treatment.
For KRAS forms other than G12C, there is no authorised tablet yet.
Ask for the exact name of your change. It decides the treatment.
Why this page
Today, lung cancer is told apart by changes in the tumour. Many of them are rare. Rare does not mean unimportant: for most of them, a medicine is now authorised.
Changes found in about 4 in 100 people with NSCLC or more have their own page: EGFR, KRAS G12C, ALK. ROS1 shares the ALK page. All others are explained here, each in the same way.
Chemotherapy. New medicines against these forms are being tested in trials.
Simplified, as of November 2026, based on ESMO, Onkopedia and the EU authorisations. Examples without ranking. What is available and paid for differs by country.
Each change in turn
BRAF V600E in lung cancer
Mutationin about 1 to 2 in 100 people with NSCLC
A gene in the growth pathway that is permanently active. Two tablets together, often as the first treatment.
First treatment
Two tablets together (BRAF and MEK inhibitors).e.g.+or+